Acute conjunctivitis treatment market is because of increasing aging of the population, increase in ophthalmic diseases prevalence rate, rise in investments for the development of new products, growing conscious towards health, funded eye check-up campaigns by governments of different countries are driving the growth of acute conjunctivitis treatment market. Moreover, increasing awareness about various eye infections and rise in blindness prevalence among geriatric population boosting the market growth of acute conjunctivitis treatment. However, due to the stringent regulations in drugs developmental process and side effects associated with the various antibiotics would hamper the adoption of eye infection pharmaceutical treatment, in turn, hinder the market growth.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-acute-conjunctivitis-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

Acute conjunctivitis treatment market is segmented on the basis of type, dosage form, drug class, distribution channel, and geography

Based on the type, acute conjunctivitis treatment market is segmented as:
Viral Conjunctivitis
Bacterial Conjunctivitis
Allergic Conjunctivitis
Conjunctivitis Caused by Irritants

Based on dosage form, acute conjunctivitis treatment market is segmented as:
Gels and Cream
Eye drops
Tablets and Capsules

Based on the drug class, acute conjunctivitis treatment market is segmented as:
Antihistamines
Antibiotic
Mast cell stabilizers
Anti-inflammatory drugs
Others

Based on distribution channel, acute conjunctivitis treatment market is segmented as:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies


To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-acute-conjunctivitis-treatment-market/#ulp-c654SbFYO64MsOhu

As per the clinical study conducted by scientists Neal P. Barney and Amir A. Azari in 2013, which was published in Journal of American Medical Association (JAMA), states that bacterial conjunctivitis accounts for about 50% of conjunctivitis cases in U.S. and also estimated that the bacterial conjunctivitis incidence rate was anticipated as 135 in 10,000.Top pharma companies are dominating the market owing to different factors like sale, strong global presence, and efficient distribution network, R&D investments, products of superior quality, and strong brand image. In 2016, Irish based pharma company Shire’s Xiidra received U.S.FDA approval which is used to treat dry-eye. In 2015, Bausch & Lomb Inc. acquired Doctor’s Allergy Formula in order to expand its ophthalmic product portfolio,

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-acute-conjunctivitis-treatment-market/#ulp-14mlyhjMGhVjZqa3

On the basis of geographical regions, acute conjunctivitis market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is dominating global acute conjunctivitis market owing to few factors like rising more number of approvals by FDA, various strong strategies by pharma companies, rise in R&D investments. The European market is the second largest market for acute conjunctivitis treatment. Increase in prevalence and growing awareness of conjunctivitis and its treatments are leading the growth of Asia Pacific acute conjunctivitis treatment market. The Middle East and Africa acute conjunctivitis treatment market is expected to have limited growth because of lack of traditional healthcare practices and slow adoption of new products and therapies.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-acute-conjunctivitis-treatment-market/

Some of the players in global acute conjunctivitis treatment market are Pfizer, Inc. (U.S), Allergan Inc. (Ireland), Boehringer Ingelheim GmbH (Germany), CIBA Vision Ophthalmics (U.S), Sanofi (France), Novartis AG (Switzerland), Bausch & Lomb Inc. (Valeant) (Canada), Merck & Co., Inc. (U.S), and Santen Pharmaceuticals Co. Ltd.(Japan)



Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: [email protected]
Toll Free(US): +1-866-598-1553"